Your browser doesn't support javascript.
loading
Factors affecting the benefit of insulin dose intensification in people with Type 2 diabetes: an analysis from the OpT2mise randomized trial.
Schütz-Fuhrmann, I; Castañeda, J; Reznik, Y; Aronson, R; Conget, I; Liabat, S; Runzis, S; de Portu, S; Cohen, O.
Afiliação
  • Schütz-Fuhrmann I; Department of Endocrinology, City Hospital Hietzing, Vienna, Austria.
  • Castañeda J; Medtronic Bakken Research Center, Maastricht, The Netherlands.
  • Reznik Y; Department of Endocrinology, University of Caen Côte de Nacre Regional Hospital Center, Caen, France.
  • Aronson R; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada.
  • Conget I; Diabetes Unit, Endocrinology and Nutrition Department, University Hospital Clinic, Barcelona, Spain.
  • Liabat S; Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
  • Runzis S; Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
  • de Portu S; Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
  • Cohen O; Institute of Endocrinology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Diabet Med ; 34(2): 291-292, 2017 02.
Article em En | MEDLINE | ID: mdl-27770589
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Insulina Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Insulina Idioma: En Ano de publicação: 2017 Tipo de documento: Article